You are viewing the site in preview mode
Skip to main content
|
Prognostic
| |
|
Immunoscore
| |
|
Therapeutic
| |
|
Conventional Therapies
| |
|
Chemotherapy
| |
|
Radiation therapy
| |
|
ITAs - Passive
| |
|
Cellular Therapy
| |
|
Adoptive T and NK cells
| |
|
CAR T cells
| |
|
ITAs - Active & Specific
| |
|
Monoclonal Antibodies
| |
|
Tumor-targeting
| |
|
Immune-targeting, including checkpoint inhibitors
| |
|
Vaccines
| |
|
In situ Vaccines
| |
|
Cell-based Vaccines
| |
|
Dendritic cell–based Vaccines
| |
|
Non–cell-based Vaccines
| |
|
ITAs - Active & Nonspecific
| |
|
Cytokines
| |
|
IDO Inhibitors
| |
-
CAR chimeric antigen receptor, ITA immune-targeted agent, IDO indoleamine-2,3-dioxygenase
